Classification criteria and treatment modalities in primary Sjögren’s syndrome

A. Fazaa(Hôpital Mongi Slim), Jacques‐Eric Gottenberg(Centre National de la Recherche Scientifique), Christelle Sordet, Arnaud Theulin(Hôpitaux Universitaires de Strasbourg), Jean Sibilia(Immunologie, Immunopathologie et Chimie Thérapeutique), Emmanuel Chatelus(Laboratoire National de Référence), Tristan Bourcier(Hôpitaux Universitaires de Strasbourg)
Expert Review of Clinical Immunology
March 20, 2014
10.1586/1744666x.2014.897230
Cited by 7

Related Papers

<i>MUC5B</i> Promoter Variant and Rheumatoid Arthritis with Interstitial Lung Disease
|New England Journal of Medicine|2018|501
Incidence and Prevalence of Systemic Sclerosis: A Systematic Literature Review
|Seminars in Arthritis and Rheumatism|2007|456
Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group
|Annals of the Rheumatic Diseases|2014|432
Lymphomas in Patients With Sjogren's Syndrome Are Marginal Zone B-Cell Neoplasms, Arise in Diverse Extranodal and Nodal Sites, and Are Not Associated With Viruses
|Blood|1997|346
Hydroxychloroquine in systemic lupus erythematosus: results of a French multicentre controlled trial (PLUS Study)
|Annals of the Rheumatic Diseases|2012|207